Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Nike
NKE
5
Palantir
PLTR
JP Stock MarketDetailed Quotes
4502 Takeda Pharmaceutical
- 4477.0
- -63.0-1.39%
20min DelayMarket Closed Apr 4 15:30 JST
7.12TMarket Cap49.11P/E (Static)
4513.0High4437.0Low8.95MVolume4474.0Open4540.0Pre Close40.03BTurnover4573.052wk High0.61%Turnover Ratio1.59BShares3852.052wk Low129.68EPS TTM6.62TFloat Cap8080.0Historical High49.11P/E (Static)1.48BShs Float2894.5Historical Low91.16EPS LYR1.67%Amplitude192.00Dividend TTM0.95P/B100Lot Size4.29%Div YieldTTM
About Takeda Pharmaceutical Company
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Company Profile
Symbol4502
Company NameTakeda Pharmaceutical
Founded1925-01-29
MarketTSE Prime
Employees49281
Fiscal Year Ends03-31
Address1-1, Nihonbashi-Honcho 2-Chome Chuo-ku
Zip Code540-8645
Phone06-6204-2111
Websitewww.takeda.com
Company Executives
- Name
- Position
- Salary
- Akiko Amakawa
- Corporate Strategy Officer and Chief Executive Officer Chief of Staff
- --
- Christophe Weber
- Director, President and Chief Executive Officer; Head of Global Business of Takeda Pharmaceuticals U.S.a., Inc.
- 1.70B
- Takako Ohyabu
- Chief Global Corporate Affairs and Sustainability Officer
- --
- Mwana Lugogo
- Chief Ethics and Compliance Officer
- --
- Lauren Duprey
- Chief Human Resources Officer
- --
- Milano Furuta
- Director and Chief Financial Officer
- --
- Gabriele Ricci
- Chief Data and Technology Officer
- --
- Elaine Shannon
- Global Quality Officer
- --
- Marcello Agosti
- Global Business Development Officer
- --
- Dr. Thomas Wozniewski, PhD
- Global Manufacturing and Supply Officer
- --
- Teresa Marie Bitetti
- President, Global Oncology Business Unit
- --
- Ramona Sequeira
- President, Global Portfolio Division
- --
- Julie Kim
- President, U.S. Business Unit and U.S. Country Head
- --
- Asuka Miyabashira
- President, Japan Pharma Business Unit
- --
- Masami Iijima
- Chairman of the Board
- 43.00M
- Giles Platford
- President, Plasma-Derived Therapies Business Unit
- --
- Andrew S. Plump, M.D.
- Director and President, Research and Development
- 12.00M
- Miki Tsusaka
- Independent Director
- 32.00M
- Kimberly A. Reed
- Independent Director
- 41.00M
- Emiko Higashi
- Independent Director
- 49.00M
- Yoshiaki Fujimori
- Independent Director
- 40.00M
- Michel Orsinger
- Independent Director
- 46.00M
- Koji Hatsukawa
- Independent Director
- 43.00M
- Jean-Luc Butel
- Independent Director
- 38.00M
- Ian T. Clark
- Independent Director
- 44.00M
- Dr. Steven Gillis, Pd.D
- Independent Director
- 44.00M
- Dr. John M. Maraganore,PhD
- Independent Director
- 39.00M
- Yoshihiro Nakagawa
- Global General Counsel
- --